Picture of virus under microscope

Research under the microscope...

The Strathprints institutional repository is a digital archive of University of Strathclyde research outputs.

Strathprints serves world leading Open Access research by the University of Strathclyde, including research by the Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS), where research centres such as the Industrial Biotechnology Innovation Centre (IBioIC), the Cancer Research UK Formulation Unit, SeaBioTech and the Centre for Biophotonics are based.

Explore SIPBS research

Discovery and biological evaluation of the novel naturally occurring diterpene pepluanone as antiinflammatory agent

Corea, G. and Fattorusso, E. and Lanzotti, V. and Di Meglio, P. and Maffia, P. and Grassia, G. and Ialenti, A. and Ianaro, A. (2005) Discovery and biological evaluation of the novel naturally occurring diterpene pepluanone as antiinflammatory agent. Journal of Medicinal Chemistry, 48 (22). pp. 7055-7062. ISSN 0022-2623

Full text not available in this repository. (Request a copy from the Strathclyde author)

Abstract

From the whole plant of Euphorbia peplus L., a new diterpene based on a rare pepluane skeleton, named pepluanone (1), was isolated together with a known pepluane diterpene (2). The stereostructure of pepluanone was determined on the basis of an extensive NMR study, MS data, and chemical reaction. The ability of these compounds to act as antiinflammatory agents has been evaluated for the first time by in vivo tests on carrageenin-induced rat paw edema, an experimental model of acute inflammation. Comparison of the bioactivity of pepluanone and compound 2 in terms of chemical structure, evidenced the high efficiency of pepluanone and the absence of appreciable activity for compound 2, thus giving a first insight into the structure−activity relationship. Further in vitro experiments performed on pepluanone let us hypothesize that its activity could be explained in reducing the production of nitric oxide, prostaglandin E2, and TNF-α by inhibiting the expression of inducible nitric oxide synthase, cyclooxygenase-2, and TNF-α mRNA through the down-regulation of NF-κB binding activity.